Name | Title | Contact Details |
---|---|---|
Paul Brennan |
Chief Business Officer | Profile |
Alexander Rothwell |
Chief Financial Officer | Profile |
Bruce Cousins |
President and Chief Financial Officer | Profile |
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
Wilmington Pharmaceuticals is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Therigy® is a patient-focused specialty therapy management company. As an industry pioneer, Therigy continues to lead the specialty pharmacy market as the top choice in technology and consulting solutions—with the best possible outcomes for patients in mind.
We provide deep scientific knowledge, global understanding and broad expertise to enhance market access and medical communications for improved health outcomes.
Odyssey Behavioral Health consists of a growing portfolio of quality behavioral health facilities with evidence-based clinical care.